R Jeffrey Karnes

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, Rochester, Minnesota Electronic address
    J Urol 190:2047-53. 2013
  2. pmc A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:835-42. 2012
  3. doi request reprint The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status
    R Jeffrey Karnes
    Department of Urology, Laboratory Medicine and Pathology, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:8994-9002. 2010
  4. doi request reprint Surgery for urethral cancer
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Urol Clin North Am 37:445-57. 2010
  5. doi request reprint Hospitalization costs for radical prostatectomy attributable to robotic surgery
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Eur Urol 64:11-6. 2013
  6. ncbi request reprint Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement
    Igor Frank
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:1803-8. 2004
  7. doi request reprint Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 189:2092-8. 2013
  8. pmc Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:3930-6. 2008
  9. doi request reprint Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence
    Stephen A Boorjian
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Eur Urol 59:893-9. 2011
  10. pmc The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis
    Christopher J Weight
    University of Minnesota, Department of Urology, Minneapolis, MN 55455, USA
    Eur Urol 63:1021-7. 2013

Detail Information

Publications70

  1. doi request reprint Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, Rochester, Minnesota Electronic address
    J Urol 190:2047-53. 2013
    ..We report a validation study of a genomic classifier that predicts metastasis after radical prostatectomy in a high risk population...
  2. pmc A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:835-42. 2012
    ....
  3. doi request reprint The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status
    R Jeffrey Karnes
    Department of Urology, Laboratory Medicine and Pathology, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:8994-9002. 2010
    ..In addition, although patient numbers are small, the response to adjuvant androgen deprivation therapy is associated with ERG status, showing more significant treatment effect in ERG(+) patients...
  4. doi request reprint Surgery for urethral cancer
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Urol Clin North Am 37:445-57. 2010
    ..Surgical extirpation remains the standard for most patients, with the addition of chemotherapy and radiation therapy in select patients. The surgical approach to urethral cancer depends largely on the location and extent of the tumor...
  5. doi request reprint Hospitalization costs for radical prostatectomy attributable to robotic surgery
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Eur Urol 64:11-6. 2013
    ....
  6. ncbi request reprint Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement
    Igor Frank
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:1803-8. 2004
    ..The objective of this study was to assess the ability of these markers to predict disease-associated outcomes and response to chemotherapy in a cohort of patients with LN-positive TCC...
  7. doi request reprint Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 189:2092-8. 2013
    ..In this context we determined whether quality of life and prediction instruments for prostate cancer have been adopted by radiation oncologists and urologists in the United States...
  8. pmc Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:3930-6. 2008
    ..The objective of this study was to develop a model predictive of outcome in this group of patients...
  9. doi request reprint Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence
    Stephen A Boorjian
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Eur Urol 59:893-9. 2011
    ..The natural history of biochemical recurrence (BCR) after radical retropubic prostatectomy (RRP) is variable and does not always translate into systemic progression or prostate cancer (PCa) death...
  10. pmc The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis
    Christopher J Weight
    University of Minnesota, Department of Urology, Minneapolis, MN 55455, USA
    Eur Urol 63:1021-7. 2013
    ..Lower urinary tract symptoms (LUTS) are common and have been associated with the subsequent diagnosis of prostate cancer (PCa) in population cohorts...
  11. pmc Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL
    Brant A Inman
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 113:1544-51. 2008
    ..The authors evaluated the long-term outcomes of men with prostate cancer and very high (> or =50 ng/mL) preoperative serum prostate-specific antigen (PSA) values that were treated with radical prostatectomy...
  12. pmc Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    Cancer 117:2883-91. 2011
    ..The long-term survival of patients with high-risk prostate cancer was compared after radical prostatectomy (RRP) and after external beam radiation therapy (EBRT) with or without adjuvant androgen-deprivation therapy (ADT)...
  13. doi request reprint Dynamic prediction of metastases after radical prostatectomy for prostate cancer
    Brant A Inman
    Division of Urology, Duke University Medical Center, Durham, NC, USA
    BJU Int 108:1762-8. 2011
    ..The net result is a dynamic tool that renders clinically relevant predictions that change as the patient's clinical status changes throughout the postoperative course...
  14. doi request reprint Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 189:514-20. 2013
    ..We described population level trends in radical prostatectomy for patients with prostate cancer by hospitals with robotic surgery, and assessed whether socioeconomic disparities exist in access to such hospitals...
  15. doi request reprint Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer
    Brian J Linder
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Urol 20:798-805. 2013
    ..To evaluate the impact of adjuvant hormonal therapy after radical prostatectomy on overall survival in high-risk prostate cancer patients, stratified by comorbidity status...
  16. ncbi request reprint Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    BJU Int 101:299-304. 2008
    ..To investigate whether the clinical and pathological outcomes after radical retropubic prostatectomy (RRP) have changed since the advent of prostate-specific antigen (PSA) testing for patients with Gleason 8-10 cancers...
  17. doi request reprint Contemporary trends of in-hospital complications and mortality for radical cystectomy
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 110:1163-8. 2012
    ..About 29% and 2% of patients undergoing RC will experience a postoperative complication or die during hospitalisation, respectively...
  18. pmc Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer
    Farhad Kosari
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Pathol 181:34-42. 2012
    ..These results validate our approach for finding PCa field effect alterations and demonstrate a PCa transcriptome fingerprint in nonneoplastic cells in prostates containing cancer...
  19. doi request reprint Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy?
    Christopher R Mitchell
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Urology 78:868-72. 2011
    ..Additionally, the effect of obesity on the serum PSA level might cause relative hemodilution and account for the decreased predictive ability of the PSA level to determine the tumor volume in the modern era...
  20. doi request reprint The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy
    Stephen A Boorjian
    Department of Urology, Health Sciences Research, and Laboratory Medicine and Pathology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 181:95-104; discussion 104. 2009
    ..We investigated the association of Gleason score discordance with postoperative systemic progression and death from prostate cancer...
  21. ncbi request reprint Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
    Stephen A Boorjian
    Department of Urology and Division of Biostatistics, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 178:864-70; discussion 870-1. 2007
    ..We examined the impact of lymph node metastases on the outcome of patients following radical prostatectomy and investigated prognostic factors that affect survival...
  22. doi request reprint Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer
    Irina V Kovtun
    Departments of Molecular Pharmacology and Experimental Therapeutics, Laboratory Medicine and Pathology, Molecular Medicine, and Urology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 73:3275-84. 2013
    ..We show evidence that LCM, WGA, and NGS of adjacent tumor regions provide an important tool in deciphering lineage relationships and discovering chromosomal alterations associated with tumor progression...
  23. doi request reprint Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 112:478-84. 2013
    ..Furthermore, patients treated surgically at high-volume and teaching hospitals are more likely to receive continent diversions...
  24. doi request reprint Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy
    Manuel S Eisenberg
    Departments of Urology and Health Sciences Research LR, EJB, Mayo Clinic, Rochester, Minnesota
    J Urol 190:1735-41. 2013
    ..We evaluated long-term outcomes in patients with pT3aN0 disease and determined predictors of recurrence in these men...
  25. pmc The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort
    Mohammed Nabhan
    Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:540-7. 2012
    ..To determine whether higher intensity of prostate-specific antigen (PSA) surveillance was associated with earlier detection of biochemical recurrence (BCR) or survival...
  26. pmc Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases
    Grant Chavin
    Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 15:2174-80. 2009
    ..Prostate cancer cells uniformly express the immune cell inhibitory B7-H3 ligand. Enhanced B7-H3 expression correlates with increased disease progression and cancer-specific death after radical prostatectomy (RP)...
  27. doi request reprint Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy
    Matthew K Tollefson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 77:1161-5. 2011
    ..However, these findings have not been studied in a large cohort of patients with prostate cancer...
  28. doi request reprint The effect of Gleason score on the predictive value of prostate-specific antigen doubling time
    Matthew K Tollefson
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 105:1381-5. 2010
    ....
  29. doi request reprint Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells
    Meilan He
    Department of Urology, Mayo Clinic, Rochester, Minnesota
    Prostate 69:1643-50. 2009
    ..Tumor suppressor genes retinoic acid receptor beta (RARbeta) and PDLIM4 are hypermethylated and silenced in prostate cancer (PCa) tissues and PCa cell lines compared to normal prostate cells...
  30. doi request reprint Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates
    Brian J Linder
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Int J Urol 20:860-4. 2013
    ..To examine the ability of standard and saturation transrectal prostate biopsy techniques to predict appropriate candidates for active surveillance...
  31. doi request reprint The impact of clinical stage on prostate cancer survival following radical prostatectomy
    Matthew K Tollefson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 189:1707-12. 2013
    ..In this study we evaluated the association of clinical stage with death from prostate cancer in men who underwent radical prostatectomy and assessed for changes in its prognostic value over time...
  32. doi request reprint 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer
    Christopher R Mitchell
    Departments of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 110:1709-13. 2012
    ..Our study shows that with long-term follow-up RP provides excellent oncological outcomes even at 20 years. While most men do require a multimodal treatment approach, many men can be managed successfully with RP alone...
  33. doi request reprint Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy
    Stephen A Boorjian
    Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
    J Urol 188:1761-6. 2012
    ..We evaluated the long-term outcome of patients with biochemical recurrence following radical prostatectomy with adjuvant radiation therapy and determined predictors of systemic progression in these men...
  34. pmc Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer
    Benjamin R Kipp
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    J Mol Diagn 11:148-54. 2009
    ..33, 95% CI 0.13, 0.83; P = 0.019), suggesting that the percentage of abnormal cells independently predicts cancer recurrence and progression to invasive disease in patients with a history of non-invasive bladder cancer...
  35. doi request reprint Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 179:1354-60; discussion 1360-1. 2008
    ..We externally validated the ability of the risk groups to predict clinical progression, and cancer specific and overall survival following radical prostatectomy, and identify predictors of outcome in patients with high risk disease...
  36. pmc Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer
    Saswati Mahapatra
    Department of Urology and Biochemistry Molecular Biology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    AAPS J 13:365-77. 2011
    ....
  37. doi request reprint Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model
    Matthew K Tollefson
    Department of Urology, Mayo Clinic, Rochester, MN
    Mayo Clin Proc 89:308-18. 2014
    ..To determine the role of cellular proliferation and other biopsy-based features in the prediction of prostate cancer mortality...
  38. pmc Hypermethylation of genes for diagnosis and risk stratification of prostate cancer
    Donkena Krishna Vanaja
    Department of Urology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Cancer Invest 27:549-60. 2009
    ..Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer...
  39. doi request reprint A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis
    Christopher J Weight
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Urology 80:484.e17-22. 2012
    ..Exisulind and its analogs have been shown to induce apoptosis in vitro in many cancer cell lines, including CaP cell lines without affecting normal human cells...
  40. doi request reprint Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series
    J Mikel Hubanks
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Eur Urol 61:878-84. 2012
    ..Patients with newly diagnosed localized prostate cancer who choose surgery want cure and decent quality of life, namely, pad-free urinary control and, often, erectile function satisfactory for sexual intercourse...
  41. pmc Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells
    Saswati Mahapatra
    Department of Urology, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Evid Based Complement Alternat Med 2012:303019. 2012
    ..EENL treatment could have a potential therapeutic role during cancer progression...
  42. doi request reprint Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer
    Benjamin R Kipp
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Am J Clin Pathol 130:552-9. 2008
    ..The data from this study suggest that chromosomal abnormalities detectable by FISH in urothelial carcinoma are also common in rarer histologic variants of bladder cancer...
  43. doi request reprint Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    J Endourol 22:1471-6. 2008
    ..To investigate the impact of body mass index (BMI) on pathologic and functional outcomes after robot-assisted laparoscopic prostatectomy (RALP)...
  44. doi request reprint Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Clin Pract Urol 5:329-39. 2008
    ..In this Review, we describe our approach to surgical resection in patients who have renal cell carcinoma with inferior vena cava thrombus, and outcomes for the management of patients with this disorder...
  45. doi request reprint Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life
    Eric C Umbreit
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN, USA
    J Am Coll Surg 210:232-9. 2010
    ..We evaluated the feasibility and oncologic durability of performing prostate biopsy and open radical retropubic prostatectomy (RRP) in patients who have previously undergone proctocolectomy and ileal pouch-anal anastomosis (PC-IPAA)...
  46. doi request reprint Identification of prognostic biomarkers for prostate cancer
    Farhad Kosari
    Mayo Clinic Cancer Center, Department of Laboratory Medicine and Pathology, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:1734-43. 2008
    ..This paper describes a process for the identification of genes that can report on the aggressiveness of prostate tumors and thereby add to the information provided by current pathologic analysis...
  47. doi request reprint Radical retropubic prostatectomy in immunosuppressed transplant recipients
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55902, USA
    J Urol 179:1349-52; discussion 1352-3. 2008
    ..We reviewed our experience with radical retropubic prostatectomy in patients with solid organ transplants...
  48. doi request reprint Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy
    Matthew K Tollefson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 184:925-9. 2010
    ..In this study we investigate the need for yearly prostate specific antigen measurements in patients with surgically treated low risk prostate cancer...
  49. pmc Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer
    Stephen J Murphy
    Department of Molecular Medicine, Mayo Clinic, Medical Sciences Building 2, 200 First St, SW, Rochester, MN 55905, USA
    DNA Res 19:395-406. 2012
    ..The described methodology provides a mechanism of efficiently defining these events in limited pure populations of tumour tissue, aiding in the derivation of genomic aberrations that initiate cancer and drive cancer progression...
  50. doi request reprint A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 61:664-75. 2012
    ..Numerous series have reported cancer control and quality-of-life (QoL) outcomes following treatment with radical prostatectomy (RP)...
  51. doi request reprint Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy
    Matthew K Tollefson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 185:1686-90. 2011
    ..Therefore, we determined the prognostic value of administrative claims data for reporting urinary incontinence and erectile dysfunction after radical prostatectomy...
  52. doi request reprint Use of high fidelity operating room simulation to assess and teach communication, teamwork and laparoscopic skills: initial experience
    Matthew T Gettman
    Department of Urology, and the Multidisciplinary Simulation Center, Mayo Clinic, Rochester, Minnesota, USA
    J Urol 181:1289-96. 2009
    ..We evaluated and taught teamwork, communication and laparoscopic skills to urology residents in a simulated operating room...
  53. ncbi request reprint Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome
    Igor Frank
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:2425-31. 2003
    ..However, some patients are cured by radical cystectomy alone. The goal of this study was to identify predictors of survival in this cohort...
  54. doi request reprint Effect of metformin on prostate cancer outcomes after radical prostatectomy
    Dharam Kaushik
    Department of Urology, Mayo Clinic, Rochester, MN
    Urol Oncol 32:43.e1-7. 2014
    ..However, there are conflicting findings on the effect of metformin on established cases of prostate cancer. In this study we evaluated the effect of metformin on survival and pathologic outcomes in established prostate cancer...
  55. pmc Prognostic value of discs large homolog 7 transcript levels in prostate cancer
    Christian R Gomez
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota, United States of America Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America Division of Preventive and Occupational Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 8:e82833. 2013
    ....
  56. doi request reprint Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy
    Matthew K Tollefson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA Electronic address
    Urol Oncol 31:1483-8. 2013
    ..Therefore, the objective of our study was to evaluate the impact of baseline renal function on oncologic outcomes and overall survival following radical prostatectomy...
  57. doi request reprint The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 187:2011-7. 2012
    ..We describe the incidence of hospital acquired adverse events in radical cystectomy, and characterize its relationship with in-hospital mortality, length of stay and hospitalization costs...
  58. ncbi request reprint B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy
    Timothy J Roth
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 67:7893-900. 2007
    ..Moreover, B7-H3 encompasses a novel diagnostic and potential therapeutic target for the clinical management of prostate cancer and, perhaps, other malignancies as well...
  59. pmc The association between statin use and the diagnosis of prostate cancer in a population based cohort
    Rodney H Breau
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Urol 184:494-9. 2010
    ..The effect of statin medication use on the risk of prostate cancer is unknown...
  60. doi request reprint Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience
    David A Woodrum
    Department of Radiology, Mayo Clinic, Rochester, MN
    Urology 82:870-5. 2013
    ..To establish the feasibility of magnetic resonance imaging (MRI)-guided cryoablation in patients with previous radical prostatectomy and MRI visualized biopsy-proven local recurrence of prostate adenocarcinoma...
  61. doi request reprint Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment
    Christopher R Mitchell
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 189:1308-13. 2013
    ..We examined the performance of (11)C-choline positron emission tomography/computerized tomography for its ability to delineate prostate cancer distribution and extent after initial therapy...
  62. ncbi request reprint Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization
    Benjamin R Kipp
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Urol 173:401-4. 2005
    ..We evaluated fluorescence in situ hybridization (FISH) for assessing the response to therapy in patients with superficial bladder cancer receiving bacillus Calmette-Guerin or other intravesical therapies...
  63. ncbi request reprint Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy
    Michael L Blute
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 178:440-5; discussion 444. 2007
    ..We describe the indications, technique, complications and outcomes of vena caval interruption during nephrectomy with tumor thrombectomy...
  64. doi request reprint Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal
    Benjamin R Kipp
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Urol 179:1296-301; discussion 1301. 2008
    ..We evaluated the usefulness of fluorescence in situ hybridization in the treatment of patients with equivocal cytology...
  65. doi request reprint Radical prostatectomy for high-risk prostate cancer
    R Jeffrey Karnes
    Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Jpn J Clin Oncol 40:3-9. 2010
    ..For these reasons, RRP remains the best single treatment of high-risk PC in operable patients...
  66. doi request reprint Changes in specimen preparation method may impact urine cytologic evaluation
    Jesse S Voss
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Clin Pathol 130:428-33. 2008
    ..7% vs 4.1%; P<.001) increased. After 1 year of follow-up, there was no significant difference in the percentage of patients diagnosed with bladder carcinoma between the 2 methods for all cytologic categories...
  67. ncbi request reprint A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine
    Kevin C Halling
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Urol 167:2001-6. 2002
    ..We determine the sensitivity and specificity of various assays for the detection of urothelial carcinoma...
  68. doi request reprint Vitamins and prostate cancer risk
    Krishna Vanaja Donkena
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Molecules 15:1762-83. 2010
    ..This review will provide up-to-date information regarding the recent outcomes of laboratory, epidemiology and/or clinical trials on the effects of vitamins on PC prevention and/or treatment...
  69. doi request reprint Urology resident training with an unexpected patient death scenario: experiential learning with high fidelity simulation
    Matthew T Gettman
    Department of Chaplain Services, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 180:283-8; discussion 288. 2008
    ..We evaluated resident performance during an unexpected patient death scenario involving high fidelity simulation. We also studied simulation as a tool to teach and assess nontechnical skills in urology...
  70. doi request reprint Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells
    Aiyu Gong
    Department of Urology, and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905 USA
    Mol Nutr Food Res 53:878-86. 2009
    ....